PLSE: First‑in‑Human nPulse Study Shows 100% Posterior Box Isolation
Rhea-AI Filing Summary
Pulse Biosciences reported late-breaking first‑in‑human feasibility results for its nPulse™ Cardiac Surgical System. The study has treated 44 patients across three investigators, with an initial cohort of 24 patients evaluated by electroanatomical mapping about ~3 months after ablation. Key clinical outcomes: posterior box isolations were acutely successful in 100% of cases in the high‑dose cohort; pulmonary vein isolation (PVI) success per vein at ~3 months was 94% (63 of 67); average total ablation time was 50 seconds with an average of 13 applications. No esophageal or phrenic nerve damage and no ablation‑related severe or major adverse events were reported. The company attached a press release as Exhibit 99.1 describing presentation of these results at the European Association for Cardio‑Thoracic Surgery annual meeting.
Positive
- 94% PVI success per vein at ~3 months (63/67)
- 100% acute posterior box isolation in the high‑dose cohort
- No esophageal or phrenic nerve injuries reported
- No ablation‑related severe or major adverse events reported
- Average total ablation time 50 seconds with 13 applications
Negative
- Limited sample size: only 24 patients had ~3‑month electroanatomical mapping
- Short follow‑up of approximately ~3 months, limiting durability assessment
- Early feasibility stage: results require confirmation in larger, multi‑center studies
- No financial impact or regulatory pathway disclosed in the filing
Insights
Early safety and durability signals appear favorable in a small first‑in‑human cohort.
The study reports 94% PVI success per vein at roughly ~3 months and 100% acute posterior box isolation in the high‑dose cohort, suggesting the device can achieve electrical isolation efficiently with an average 50‑second total ablation time and 13 applications. The absence of esophageal or phrenic nerve injuries and no reported severe or major ablation‑related adverse events are positive safety signals.
These results depend on limited patient numbers (24 with mapping data, 44 treated overall) and short follow‑up; confirmatory larger studies and longer‑term durability data beyond ~3 months are needed to assess sustained efficacy and rare adverse events within a typical clinical adoption timeline of 12–36 months.
Operational metrics indicate fast procedures, which may reduce procedure time if replicated.
The reported 50‑second average ablation time and 13 applications imply a compact energy delivery profile that could shorten case duration compared with conventional methods; this could influence hospital workflow and cost if validated in broader cohorts. The presentation at a major society meeting supports peer engagement and visibility.
Key dependencies are scalability of results across more operators and centers, reimbursement acceptance, and demonstration of long‑term durability past ~3 months. Watch for planned pivotal study designs, enrollment timelines, and any regulatory submissions in the next 12–24 months.
8-K Event Classification
FAQ
What results did Pulse Biosciences (PLSE) report from the nPulse first‑in‑human study?
How many patients were treated in the study referenced by PLSE?
Were there any safety issues reported in the PLSE filing?
What procedural metrics did PLSE disclose for the nPulse system?
Has Pulse Biosciences provided long‑term durability data?
